|Bid||16.70 x 1200|
|Ask||17.00 x 4000|
|Day's Range||16.36 - 17.40|
|52 Week Range||5.00 - 51.90|
|PE Ratio (TTM)||22.45|
|Earnings Date||Mar 14, 2018 - Mar 19, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Dr. Comer is a Professor of Neurobiology in the Department of Psychiatry at the College of Physicians and Surgeons at Columbia University. Dr. Comer began her talk with an overview of the epidemiology of the opioid epidemic. The following graphic shows the startling increase in drug overdose deaths from 1999 to 2016.
SANTA MONICA, Calif., May 08, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the first ...
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, will host a Key Opinion Leader (KOL) luncheon on Medications for Addictions and Related Disorders on Thursday, May 10 in New York City. The event will feature presentations by KOLs Sandra Comer, PhD, Columbia University, Susan McElroy, MD, University of Cincinnati, and Stephanie O'Malley, PhD, Yale School of Medicine, who will discuss the current treatment landscape and unmet medical need for treating patients with substance use and eating disorders.
LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Opiant Pharma, Inc. (NASDAQ: OPNT) ("Opiant"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPNT as the Company's latest news hit the wire. On April 18, 2018, the Company, which is a specialty pharmaceutical organization developing pharmacological treatments for addictions, declared that the National Institutes of Health's National Institute on Drug Abuse (NIDA) has granted it an award of approximately $7.4 million for the development of OPNT003 (intranasal nalmefene) for opioid overdose.
Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it has been awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. “We view this NIDA grant as further validation of the potential for OPNT003 to be an important treatment for opioid overdose, a growing U.S. health epidemic,” said Roger Crystal, M.D., Chief Executive Officer of Opiant. “Fentanyl was responsible for more overdose deaths (in excess of 20,000) than either heroin or prescription opioids in 2016. Recognizing the evolution of the opioid crisis, the National Institutes of Health has called for the development of stronger, longer-acting overdose reversal products in order to address this next wave of potent synthetic opioids, like fentanyl.
NEW YORK, April 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Stock Monitor: Opiant Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free earnings report on HubSpot, Inc. (NYSE: HUBS ). If you want ...
As part of the solution to the problem, the CDC recommends that the federal government “improve access to…overdose-reversing drugs, such as naloxone” and that health departments “increase naloxone distribution to first responders, family and friends, and other community members in affected areas” (CDC). While not a treatment for opioid dependence, health authorities believe that easy access to naloxone is an essential component of battling the ongoing opioid crisis due to its effectiveness in preventing overdose deaths. On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment.
President Donald Trump promised to bring down prescription drug prices on Monday, saying U.S. citizens pay far more than people in other countries do for the same product and that his administration would announce new measures in about a month. "If you compare our drug prices to other countries in the world, in some cases it's many times higher for the exact same pill or whatever it is, in the exact same package made in the exact same plant," Trump said. Trump made the remarks during a speech in Manchester, New Hampshire that focused on the administration's efforts to battle the nation's opioid addiction crisis.
President Donald Trump spelled out in new detail several steps he favors to fight a U.S. epidemic of opioid abuse, including the execution of drug dealers, a proposal that has gained little support from drug abuse and judicial experts. At an event in Manchester, New Hampshire, Trump unveiled an anti-opioid abuse plan, including his death penalty recommendation, new funding for other initiatives and stiffer sentencing laws for drug dealers.
SANTA MONICA, Calif., March 19, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that Roger Crystal, MD., President ...
SANTA MONICA, Calif., March 07, 2018-- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions, following the recent approval by its Board ...
On February 12, 2018, Opiant Pharmaceuticals, Inc. (OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment. OPNT003 is an intranasal formulation of nalmefene, a naltrexone derivative. The U.S. continues to battle an opioid epidemic.
Dr. Roger Crystal's company was struggling to find new uses for an old drug that reverses overdoses. Then the opioid epidemic hit. Naloxone had first gone on sale in 1971 but was injected with a syringe. ...
On December 20, 2017, Opiant Pharmaceuticals, Inc. (OPNT) announced that it expects to begin receiving 90% of royalty and milestone payments related to the sale of NARCAN® Nasal Spray beginning in the first quarter of 2018. On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones were met.
On December 13, 2017, Opiant Pharmaceuticals, Inc. (OPNT) announced financial results for the first quarter of fiscal year (FY) 2018 that ended Oct. 31, 2017. The U.S. continues to battle an opioid crisis nationwide.